AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
A binary Xpovio catalyst is set for March.
BeOne terminates a MUC1-targeting project.
Welireg, Padcev, and a surprise fillip for Flare.
AZD0120’s first pivotal trial will test settings as early as the second line.
